|
- Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data
- Enhancing dementia research by integrating AI imaging solutions with real-world data platforms
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a Memorandum of Understanding (MoU) with the International Registry for Alzheimer's Disease and Other Dementias Foundation (InRAD) to accelerate global standardization of Alzheimer's and dementia-related data.
Through this agreement, Neurophet and InRAD aim to strengthen their collaboration to help establish globally harmonized standards for Alzheimer's disease and other dementias real-world data1. The partnership also seeks to enable the seamless integration of AI-based neuroimaging technologies into the broader real-world data landscape, removing one of the key practical barriers to evidence generation - namely, the lack of coordinated approaches - while acknowledging the wider adoption of these technologies in everyday clinical practice.
The partnership will focus on key initiatives including:
- Enhancing clinical workflows involving MRI and PET analysis
- Collecting and aggregating clinical imaging and quantitative data
- Validating clinical utility of AI-based analysis solutions
- Developing joint research and education programs
Neurophet's flagship products — Neurophet AQUA AD, an Alzheimer's Disease Treatment Prescription/Treatment Effect and Side Effect Monitoring Software; and Neurophet SCALE PET, a PET Image Quantitative Analysis Software; and Neurophet AQUA, a Brain MRI Analysis Software — will be available for utilization in this collaboration.
InRAD, is a free at the point-of-use registry that enables the collection of real-world data to further understanding about Alzheimer's disease, and in the future, other dementias and to support clinical management. The registry is coordinated by the independent International Registry for Alzheimer's Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in the Netherlands. The registry platform will launch later in 2025, providing a secure, regionally compliant, Azure cloud-based registry platform and governance package.
Notably, InRAD has a board composed of globally renowned researchers and clinicians in the field of dementia, including Professor Philip Scheltens, a leading expert who established the MTA scale (also known as the Scheltens scale) — the world's first MRI-based diagnostic framework for Alzheimer's disease. Professor Scheltens commented, "Collaborations such as these help to ensure a joined-up approach, reducing barriers to real world data collection in clinical practice and supporting patient care. We are very pleased to be able to announce this MoU".
Jake Junkil Been, Co-CEO of Neurophet, commented,
"This partnership marks a significant step toward expanding the clinical adoption and credibility of Neurophet's AI-powered brain imaging analysis tools on a global scale. We are committed to support clinicians and researchers worldwide by enabling standardized access to high-quality Alzheimer's disease datasets."
Neurophet continues to lead the medical AI field by forging strategic partnerships with global healthcare stakeholders.
About Neurophet
Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric brain stimulation "Neurophet tES LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
1. Perneczky et al. Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus, The Journal of Prevention of Alzheimer's Disease 2025 https://doi.org/10.1016/j.tjpad.2025.100096 |
- Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data
- Enhancing dementia research by integrating AI imaging solutions with real-world data platforms
SEOUL, South Korea, Sept. 2, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced today that it has signed a Memorandum of Understanding (MoU) with the International Registry for Alzheimer's Disease and Other Dementias Foundation (InRAD) to accelerate global standardization of Alzheimer's and dementia-related data.
Through this agreement, Neurophet and InRAD aim to strengthen their collaboration to help establish globally harmonized standards for Alzheimer's disease and other dementias real-world data1. The partnership also seeks to enable the seamless integration of AI-based neuroimaging technologies into the broader real-world data landscape, removing one of the key practical barriers to evidence generation - namely, the lack of coordinated approaches - while acknowledging the wider adoption of these technologies in everyday clinical practice.
The partnership will focus on key initiatives including:
- Enhancing clinical workflows involving MRI and PET analysis
- Collecting and aggregating clinical imaging and quantitative data
- Validating clinical utility of AI-based analysis solutions
- Developing joint research and education programs
Neurophet's flagship products — Neurophet AQUA AD, an Alzheimer's Disease Treatment Prescription/Treatment Effect and Side Effect Monitoring Software; and Neurophet SCALE PET, a PET Image Quantitative Analysis Software; and Neurophet AQUA, a Brain MRI Analysis Software — will be available for utilization in this collaboration.
InRAD, is a free at the point-of-use registry that enables the collection of real-world data to further understanding about Alzheimer's disease, and in the future, other dementias and to support clinical management. The registry is coordinated by the independent International Registry for Alzheimer's Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in the Netherlands. The registry platform will launch later in 2025, providing a secure, regionally compliant, Azure cloud-based registry platform and governance package.
Notably, InRAD has a board composed of globally renowned researchers and clinicians in the field of dementia, including Professor Philip Scheltens, a leading expert who established the MTA scale (also known as the Scheltens scale) — the world's first MRI-based diagnostic framework for Alzheimer's disease. Professor Scheltens commented, "Collaborations such as these help to ensure a joined-up approach, reducing barriers to real world data collection in clinical practice and supporting patient care. We are very pleased to be able to announce this MoU".
Jake Junkil Been, Co-CEO of Neurophet, commented,
"This partnership marks a significant step toward expanding the clinical adoption and credibility of Neurophet's AI-powered brain imaging analysis tools on a global scale. We are committed to support clinicians and researchers worldwide by enabling standardized access to high-quality Alzheimer's disease datasets."
Neurophet continues to lead the medical AI field by forging strategic partnerships with global healthcare stakeholders.
About Neurophet
Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric brain stimulation "Neurophet tES LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
1. Perneczky et al. Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus, The Journal of Prevention of Alzheimer's Disease 2025 https://doi.org/10.1016/j.tjpad.2025.100096
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Neurophet Signs MoU with InRAD to Establish Global Standards for Alzheimer's disease and Dementia Data
HONG KONG, Jan. 16, 2026 /PRNewswire/ -- As we move into 2026, Metis Global (Cook Islands) Limited ("Metis CI"), a subsidiary of Metis Global Group, has officially launched its brand-new regular savings trust plan, the "Starry Pro Plan." The plan integrates regular contributions, international trust protection, and diversified asset allocation arrangements to deliver an integrated solution for clients with medium- to long-term financial planning needs, balancing asset accumulation, structural stability, and legacy planning.
Amid rising market volatility and the increasing prevalence of cross-border allocation, clients are placing greater emphasis on the robustness of legal arrangements when planning for savings, education, or retirement objectives. Metis CI notes that the Starry Pro Plan is designed to help clients establish a forward-looking and disciplined financial structure with an accessible entry threshold.
20-Year Regular Contribution Design to Establish a Stable Financial Rhythm
The Starry Pro Plan adopts a 20-year regular savings trust structure with a standard Contribution Payment Term ("CPT"). Through consistent contributions, clients can gradually accumulate assets and establish a stable rhythm for financial planning under various market conditions. The plan is available for individual or joint applications of up to two persons and primarily targeting medium- to long-term financial goals.
Diverse Underlying Asset Design Supporting Different Financial Orientations
With respect to portfolio selection, the Starry Pro Plan provides two underlying asset options, allowing clients to make choices based on their personal circumstances and overall planning considerations at the point of application.
One option tracks the performance of the S&P 500 Index, representing a widely recognised benchmark of the U.S. equity market across multiple sectors and reflecting the long-term development of mature capital markets. The other is selected by clients from portfolios managed by third-party professional institutions, with allocations and adjustments made according to established investment strategies and market conditions.
Both approaches adopt a regular allocation mechanism to support the gradual accumulation of portfolio value across different market cycles.
International Trust Framework Strengthening Asset Protection and Legacy Arrangements
Metis CI serves as the trustee of the "Starry Pro Plan." Metis CI is a licensed trust company legally registered in the Cook Islands under the Trustee Companies Act 2014 and is regulated by the Cook Islands Financial Supervisory Commission ("FSC"). The Cook Islands is renowned for its mature common law system and the International Trusts Act 1984, and has long been regarded as an international jurisdiction with a robust legal foundation for trusts.
Under the trust structure, clients can appoint beneficiaries through a Letter of Wishes, significantly simplifying the asset transfer process. Assets are held under the independent custody of DBS Bank in Singapore and are fully segregated from the assets of Metis CI, thereby strengthening asset security.
Flexible Mechanisms Designed for Different Life Stages
Recognising that financial circumstances may change during a long-term contribution period, the "Starry Pro Plan" features several flexible options, including a Contribution Holiday, adjustments to contribution amounts, and a partial withdrawal mechanism. Throughout the CPT, clients can utilise up to 24 months of Contribution Holiday in total. Clients may also reduce the regular contribution amount or apply for partial withdrawals after the Initial Contribution Period, ensuring that their planning can adapt flexibly to changing life circumstances.
A Structure-Oriented Financial Tool
Metis CI states that the "Starry Pro Plan" emphasises structural design and medium- to long-term financial thinking. Through a defined contribution framework, a robust trust legal structure, and independent custody arrangements, the plan supports clients in building a more focused and resilient financial blueprint amid ongoing market uncertainty.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Metis "Starry Pro": Achieving Greater Wealth Stability in a Changing Landscape.
